Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 128240
Gene Symbol: NAXE
NAXE
0.010 GeneticVariation phenotype BEFREE In contrast to the previously reported patients with biallelic NAXE variants, our patients showed a milder phenotype with disease onset in early adulthood with psychosis, cognitive impairment, seizures, cerebellar ataxia and spasticity.The symptoms fluctuated. 31745726 2020
Entrez Id: 79447
Gene Symbol: PAGR1
PAGR1
0.010 Biomarker phenotype BEFREE BoNT-A injection for lower limb spasticity led to high goal achievement rates in patient-centered GAS evaluation and functional and symptomatic improvements. 31726452 2019
Entrez Id: 2588
Gene Symbol: GALNS
GALNS
0.010 Biomarker phenotype BEFREE BoNT-A injection for lower limb spasticity led to high goal achievement rates in patient-centered GAS evaluation and functional and symptomatic improvements. 31726452 2019
Entrez Id: 6558
Gene Symbol: SLC12A2
SLC12A2
0.010 AlteredExpression phenotype BEFREE Thus, long lasting reduction of spasticity by a-tsDCS via downregulation of NKCC1 may constitute a novel therapy for spasticity following spinal cord injury. 30689208 2019
Entrez Id: 7273
Gene Symbol: TTN
TTN
0.010 Biomarker phenotype BEFREE Our results suggest that both larger titin isoforms and sarcomere lengths are positively correlated with increased severity of hip displacement and may represent adaptations in response to concomitant increases in spasticity and muscle shortening. 31227002 2019
Entrez Id: 2520
Gene Symbol: GAST
GAST
0.010 Biomarker phenotype BEFREE BoNT-A injection for lower limb spasticity led to high goal achievement rates in patient-centered GAS evaluation and functional and symptomatic improvements. 31726452 2019
Entrez Id: 9496
Gene Symbol: TBX4
TBX4
0.010 GeneticVariation phenotype BEFREE Heterozygous CTNNB1 and TBX4 variants in a patient with abnormal lung growth, pulmonary hypertension, microcephaly, and spasticity. 31309540 2019
Entrez Id: 5443
Gene Symbol: POMC
POMC
0.010 AlteredExpression phenotype BEFREE Physical examination, laboratory tests, and MRI showed that he had adult-onset AMN manifestations, including spasticity and hyperactive tendon reflexes with Hoffman and Babinski signs in the limbs, difficulty in performing the heel-to-shin test, hyperpigmentation, increased levels of adrenocorticotropic hormone and very long-chain fatty acids, decreased levels of corticosteroid and serum gesterol, and salient atrophy of the cervical and thoracic spinal cord. 31557422 2019
Entrez Id: 7355
Gene Symbol: SLC35A2
SLC35A2
0.010 Biomarker phenotype BEFREE This case would expand the phenotypic spectrum of SLC35A2-related disorders to delayed myelination with spasticity and no seizures. 31231989 2019
Entrez Id: 10058
Gene Symbol: ABCB6
ABCB6
0.010 Biomarker phenotype BEFREE Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) is a rare hypomyelinating leukodystrophy characterized by infantile or childhood onset of motor developmental delay, progressive rigidity and spasticity, with hypomyelination and progressive atrophy of the basal ganglia and cerebellum due to a genetic mutation of the TUBB4A gene. 30476126 2019
Entrez Id: 7190
Gene Symbol: HSP90B2P
HSP90B2P
0.010 GeneticVariation phenotype BEFREE In humans it has been associated with phenotypes from the neurodegeneration with brain iron accumulation (fatty acid hydroxylase-associated neurodegeneration, FAHN), hereditary spastic paraplegia (HSP type SPG35) and leukodystrophy (leukodystrophy with spasticity and dystonia) spectrum. 31135052 2019
Entrez Id: 57459
Gene Symbol: GATAD2B
GATAD2B
0.010 GeneticVariation phenotype BEFREE We report a novel GATAD2B mutation in a boy exhibiting bilateral leg spasticity and white matter abnormalities on brain magnetic resonance imaging. 30482549 2019
Entrez Id: 5880
Gene Symbol: RAC2
RAC2
0.010 Biomarker phenotype BEFREE Mutations in RAB18, a member of small G protein, cause Warburg micro syndrome (WARBM), whose clinical features include vision impairment, postnatal microcephaly, and lower limb spasticity. 30721447 2019
Entrez Id: 4142
Gene Symbol: MAS1
MAS1
0.010 Biomarker phenotype BEFREE Fifty five of 121 (45%) patients after three months had developed spasticity (MAS ≥ 1), and in 19 of the 121 (15%) this spasticity was severe. 31845749 2019
Entrez Id: 102724428
Gene Symbol: SIK1B
SIK1B
0.010 Biomarker phenotype BEFREE Software Suite Training Tool for MSK Exploration and Botulinum Toxin Infiltration Based on Ultrasound Imaging for the Spasticity Treatment. 31214849 2019
Entrez Id: 8635
Gene Symbol: RNASET2
RNASET2
0.010 Biomarker phenotype BEFREE RNASET2 deficiency in humans is associated with infant cystic leukoencephalopathy, which causes psychomotor impairment, spasticity and epilepsy. 29752287 2018
Entrez Id: 213
Gene Symbol: ALB
ALB
0.010 GeneticVariation phenotype BEFREE Controllable factors included spasticity (HR=1.11;95%CI=1.04-1.20), incomplete healing before discharge (HR=5.42;95% CI=3.95-7.44), serum albumin level ≤3 g/dL (HR=1.27;95%CI=1.13-1.43), pressure ulcer stage 4 (HR=1.90;95%CI=1.41-2.54), non -muscle-based procedure (HR=3.82;95%CI=2.54-5.76), and length of hospitalization >21 days (HR=2.94;95%CI=1.60-5.40). 30012070 2018
Entrez Id: 5315
Gene Symbol: PKM
PKM
0.010 Biomarker phenotype BEFREE We showed recently (Bos et al., 2013) that specific activation of 5-HT<sub>2A</sub> receptors by TCB-2 [(4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide] upregulates KCC2 function, restores motoneuronal inhibition and reduces SCI-induced spasticity. 28844001 2018
Entrez Id: 3798
Gene Symbol: KIF5A
KIF5A
0.010 Biomarker phenotype BEFREE KIF5A gene causes autosomal dominant spastic paraplegia 10, a neurological disorder characterized by spasticity and weakness of the lower limbs (SPG10). 30411208 2018
Entrez Id: 260402
Gene Symbol: IS1
IS1
0.010 Biomarker phenotype BEFREE Baseline cranial MRI, AIS motor and sensory scale, quality of life (spinal cord impact measurement) and modified Ashworth spasticity scale, quantitative sensory testing and neurophysiological exploration were assessed at baseline, 1, 3 and 6 months following treatment.Results Thirteen had GH deficiency. 30352393 2018
Entrez Id: 3479
Gene Symbol: IGF1
IGF1
0.010 Biomarker phenotype BEFREE Moreover, beneficial effects of acupuncture on subacute phase and chronic outcomes have been reported in controlling the imbalance of IGF-1 hormone and in decreasing spasticity, pain, and the incidence of neurovegetative crisis. 30298094 2018
Entrez Id: 6509
Gene Symbol: SLC1A4
SLC1A4
0.010 GeneticVariation phenotype BEFREE In conclusion, we suggest to carefully considering SLC1A4 biallelic mutations in individuals presenting an early onset severe neurodevelopmental disorder with variable spasticity and seizures, regardless the patients' ethnic background. 29989513 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.010 Biomarker phenotype BEFREE Baseline cranial MRI, AIS motor and sensory scale, quality of life (spinal cord impact measurement) and modified Ashworth spasticity scale, quantitative sensory testing and neurophysiological exploration were assessed at baseline, 1, 3 and 6 months following treatment.Results Thirteen had GH deficiency. 30352393 2018
Entrez Id: 25859
Gene Symbol: PART1
PART1
0.010 Biomarker phenotype BEFREE Participants with chronic traumatic SCI were administered the PSFS, a self-reported spasticity measure in which the individual documents the frequency (Part 1) and severity (Part 2) of their muscle spasms. 29371700 2018
Entrez Id: 3586
Gene Symbol: IL10
IL10
0.010 AlteredExpression phenotype BEFREE The outcomes of photobiomodulation include the regeneration of cells, the stimulation of the growth of Schwann cells, a reduction in spasticity, functional improvements, a reduction in nitric oxide levels, and the upregulation of the cytokine IL10, demonstrating that this therapeutic modality can offer neuroprotection. 29742699 2018